ID: ALA3397808

Max Phase: Preclinical

Molecular Formula: C25H26F2N2O3

Molecular Weight: 440.49

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(CN[C@@H]2CO[C@H](C(c3ccc(F)cc3)c3ccc(F)cc3)C[C@H]2O)cn1

Standard InChI:  InChI=1S/C25H26F2N2O3/c1-31-24-11-2-16(14-29-24)13-28-21-15-32-23(12-22(21)30)25(17-3-7-19(26)8-4-17)18-5-9-20(27)10-6-18/h2-11,14,21-23,25,28,30H,12-13,15H2,1H3/t21-,22-,23+/m1/s1

Standard InChI Key:  VIJSZNHDABMWGG-ZLNRFVROSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 440.49

Molecular Weight (Monoisotopic): 440.1911

AlogP: 3.81

#Rotatable Bonds: 7

Polar Surface Area: 63.61

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 7.99

CX LogP: 3.88

CX LogD: 3.19

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.59

Np Likeness Score: -0.33

References

1. Santra S, Sharma H, Vedachalam S, Antonio T, Reith M, Dutta A..  (2015)  Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.,  23  (4): [PMID:25593099] [10.1016/j.bmc.2014.12.040]

Source

Source(1):

• Scientific Literature